Lanxess Ag · XETR:LXS
Lanxess — Lanxess Ag Ord — Q2 2026 Earnings Presentation
30 slides from Lanxess's earnings presentation, Aug 7, 2026
Slide 1: LANXESS – Q2 2026 results
LANXESS – Q2 2026 results Matthias Zachert, CEO I Oliver Stratmann, CFO
Slide 2: Safe harbor statement
Safe harbor statement The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United
Slide 3: Agenda
Agenda 1. Review Q2 2026 and outlook 2. Financial and business details Q2 2026 3. Appendix 3
Slide 4: Strong EBITDA improvement translating directly into FCF generation
Strong EBITDA improvement translating directly into FCF generation [in € m] Q2 EBITDA pre Q2 Free cash flow Net working capital Net financial debt 1,374 3,814 152 1,343 56 94 2,381 2,049 -29 Q1 2026 Q2 2026 Q1 2026 Q2 2026 Q1 2026 Q2 2026 FY 2022 FY 2024 Q2 2026 Improved Improved Tightly managed Vis
Slide 5: Q2: Positive prices and volumes in tandem
Q2: Positive prices and volumes in tandem Sequential price and volume growth 6% ~13% Price: 0% operational Increases successfully implemented -1% -1% -1% growth 10% also supported by 7% Middle East situation Volumes: Positive volume development since start of 2026 -1% -6% -4% Q2/25 Q3/25 Q4/25 Q1/26
Slide 6: Saltigo: Restructuring and rebalancing for future growth
Saltigo: Restructuring and rebalancing for future growth Saltigo restructuring measures: Streamlining capacity without sacrificing production & development capabilities Leverage Pharma & Specialties Strategy focus: Focus on innovative Pharma and Specialties solutions beyond agro! ~€20 m savings from
Slide 7: Bond placement of €500 m showcases strong capital market access
Bond placement of €500 m showcases strong capital market access Strong access to debt capital markets Issuance strengthens LANXESS financing profile High investor demand Liquidity of >€2 bn (€1.3bn undrawn credit Order book several times oversubscribed facilities and ~€0.9 bn cash) in the process Av
Slide 8: FY 2026 guidance confirmed: EBITDA pre expected in €450 – 550 m range
FY 2026 guidance confirmed: EBITDA pre expected in €450 – 550 m range Our view on economic LANXESS environment outlook ▪ Significant macro-economic ▪ Considerations for H2: uncertainties persist, intensified by − Continued cost streamlining to mitigate Middle East conflict inflation, savings back-en
Slide 9: Agenda
Agenda 1. Review Q2 2026 and outlook 2. Financial and business details Q2 2026 3. Appendix 9
Slide 10: LANXESS Group: Price and volume increase in tandem
LANXESS Group: Price and volume increase in tandem [€ m] Q2/2025 Q1/2026 Q2/2026 + Higher sales due to price increases and higher volumes yoy and sequentially Sales 1,466 1,378 1,561 + Substantial EBITDA pre increase of ~62% sequentially EBITDA pre 150 94 152 + Successful pass-through of strong raw
Slide 11: Consumer Protection: Sequentially solid improvement
Consumer Protection: Sequentially solid improvement while prior-year result contained positive one-time effect [€ m] Q2/2025 Q1/2026 Q2/2026 + Strong volume improvement in all businesses except for Saltigo Sales 489 458 515 + Stable pricing amid volume expansion in challenging EBITDA pre 87 62 81 ma
Slide 12: Specialty Additives: Strong improvement driven by both volume and pricing
Specialty Additives: Strong improvement driven by both volume and pricing [€ m] Q2/2025 Q1/2026 Q2/2026 + Successful price increases yoy, passing through higher input costs Sales 528 521 588 + Positive volume development in all Business units; partly EBITDA pre 58 44 77 driven by E&E and Aviation Ma
Slide 13: Advanced Intermediates: Sequentially positive improvement while markets remain soft
Advanced Intermediates: Sequentially positive improvement while markets remain soft [€ m] Q2/2025 Q1/2026 Q2/2026 + Price increases counterbalance raw material price inflation Sales 446 396 456 o Positive volume development in Pigments is offset by EBITDA pre 44 27 35 absence of volumes due to closu
Slide 14: P&L Q2: Stable earnings
P&L Q2: Stable earnings P&L [€ m] Q2/2025 Q2/2026 yoy ▪ Higher sales mainly due to Sales 1,466 1,561 6% positive price and volume effect Cost of sales -1,139 -1,231 -8% ▪ Higher selling expenses mainly due to increased volumes Selling -217 -220 -1% ▪ Reduction of G&A helped by cost G&A -64 -56 13% s
Slide 15: Strong improvement & disciplined W/C management - cash discipline remains key priority
Strong improvement & disciplined W/C management - cash discipline remains key priority Cash flow [€ m] Q2/2025 Q2/2026 ▪ Improved profit before tax Profit before tax -55 -46 ▪ Lower depreciation due to restructuring measures in prior Depreciation & amortization 217 132 year Result from investments a
Slide 16: Successful placement of €500 m bond extends balance sheet
Successful placement of €500 m bond extends balance sheet Balance sheet [€ m] 31.12.2025 30.06.2026 ▪ Total assets increased due to €500 m bond issuance Total assets 7,748 8,354 ▪ Decrease in total assets Equity ▪due stable:mPositive to €500 bond FX effects Equity 3,500 3,484 repayment, compensated
Slide 17: Q2 2026: increased sales due to better volume and pricing
Q2 2026: increased sales due to better volume and pricing Sales [€ m] Sales share [€ m] EBITDA pre [€ m] Consumer SGO LPT +1% + 6% Protection 152 150 1,561* 1,466* MPP F&F 87 -7% 81 515 CP +5% CP 489 Specialty LAB 310 Additives PLA 588 RCH SA 528 +11% SA 58 +33% 77 Advanced IPG 446 456 Intermediates
Slide 18: Targeting further structural savings until end of 2028
Targeting further structural savings until end of 2028 Actively adjusting our cost structure FORWARD! More to come… …implementation by: [in € m] 2026 2027 2028 Savings ~65 ~65 ~40 ▪ Reduction of ~550 positions worldwide Cash Outs1 ~25 ~25 ~20 across all functions ▪ Fluctuation & demographics support
Slide 19: Exceptional items (on EBIT) mainly related to Saltigo restructuring measures
Exceptional items (on EBIT) mainly related to Saltigo restructuring measures [€ m] Q2/2025 Q2/2026 H1/2025 H1/2026 thereof thereof thereof thereof Excep. Excep. Excep. Excep. D&A D&A D&A D&A Strategic realignment and restructuring -107 -81 -50 -11 -108 -81 -54 -11 (incl. FORWARD!) Strategic IT-proje
Slide 20: Guidance confirmed: ~€450 – 550 m
Guidance confirmed: ~€450 – 550 m in € m H2 considerations: ▪ Cost savings back-end loaded 246 ▪ Support from EU Anti- Dumping H1 2026 H2 2026 FY 2026 ▪ No necessity for meaningful operational improvement vs. H1 ▪ Construction recovery expected rather in 2027 FY 2026 EBITDA pre range (~€450 – 550 m)
Slide 21: P&L H1: Price & volume up, unfavorable FX effect & absence of Urethane Business
P&L H1: Price & volume up, unfavorable FX effect & absence of Urethane Business drag on earnings H1/2025 H1/2026 yoy ▪ Lower sales mainly due to Sales 3,067 2,939 -4% unfavorable FX and portfolio effect (Urethanes business in Q1 2025) Cost of sales -2,418 -2,347 3% ▪ Lower selling expenses due to Se
Slide 22: H1 2026: significantly improved cash generation
H1 2026: significantly improved cash generation Cash flow [€ m] H1/2025 H1/2026 ▪ Lower profit before tax due lower Envalior at-equity result Profit before tax -116 -182 ▪ Financial losses & gains reflect Depreciation & amortization 352 253 proceeds from divestment of Urethane Systems business in Re
Slide 23: H1 2026: FX & portfolio driven lower sales in persisting weak demand environment
H1 2026: FX & portfolio driven lower sales in persisting weak demand environment Sales [€ m] Sales share [€ m] EBITDA pre [€ m] -4% Consumer SGO LPT -13% Protection 3,067* 2,939* 283 MPP F&F 246 1,002 -3% 973 CP 160 -11% CP Specialty LAB 310 143 Additives PLA 1,073 +3% 1,109 RCH SA SA 110 +10% 121 A
Slide 24: H1 2026: balanced regional sales split
H1 2026: balanced regional sales split H1 2026 sales by region [%] Regional development of sales [€ m] Americas 3,067 2,939 Asia / Pacific Asia/Pacific 33% 552 19% +5% 577 Americas 1,064 -9% 964 EMEA 925 -6% 874 18% (excl. Germany) 30% Germany Germany 526 0% 524 EMEA H1 2025 H1 2026 (excl. Germany)
Slide 25: Agenda
Agenda 1. Review Q2 2026 and outlook 2. Financial and business details Q2 2026 3. Appendix 25
Slide 26: Housekeeping items 2026
Housekeeping items 2026 Outlook FY 2026 (in € m) Capex ~330 Operational depreciation ~340 ▪ excluding ~€130 m of intangible amortization All other segments (EBITDA pre) -140 to -150 Exceptional expenses ~80 to 100 ▪ on EBIT, based on current projects ▪ EBITDA pre impact after hedging per cent FX sen
Slide 27: Maturity profile well balanced
Maturity profile well balanced Strong access to debt capital markets ▪ Long-term financing ▪ All group financing executed without financial covenants secured Bond Bond Bond Bond Bond 2026 €500 m 2027 €500 m 2028 €600 m 2029 €600 m 2030 2031 2031+ 1000 €500 m 1.00% 0.00% 1.75% 0.625% 4.375% ▪ All gro
Slide 28: Contact details Investor Relations
Contact details Investor Relations Visit the IR website Eva Husmann Sophie Köller Catharina Kaiser Thomas Kaiser Jens Ussler Head of Investor Relations ESG Investors and Ratings Institutional Investors / Analysts Institutional Investors / Analysts Institutional Investors / Analysts Mob.: +49 151 746
Slide 29: Abbreviations
Abbreviations § Consumer Protection Specialty Additives Advanced Intermediates MPP Material Protection Products PLA Polymer Additives AII Advanced Industrial Intermediates F&F Flavors & Fragrances LAB Lubricant Additives Business IPG Inorganic Pigments SGO Saltigo RCH Rhein Chemie LPT Liquid Purific
Slide 30: Upcoming events 2026 – Proactive capital market communication
Upcoming events 2026 – Proactive capital market communication 25 mwb German Select VIII (virtual) 08 Berenberg Food Ingredients & Chemical 5 Q3 Reporting Conference, London 22 Berenberg & GS Conference, Munich 24 Baader Investment Conference, Munich Aug Sep Nov 30